News
HLTRF
2.600
-4.76%
-0.130
HLS Therapeutics GAAP EPS of -$0.07 , revenue of $14.2M
Seeking Alpha · 2d ago
*HLS Therapeutics Sees 2026 Adjusted Ebitda in Lower Half of $18.5M-$21M Guidance >HLS.T
Dow Jones · 2d ago
*HLS Therapeutics Sees 2026 Revenue Around Midpoint of $56M-$60M Guidance >HLS.T
Dow Jones · 2d ago
Press Release: HLS Therapeutics Announces Q3 2026 Financial Results
Dow Jones · 2d ago
Press Release: HLS Therapeutics Announces Q3 2026 -3-
Dow Jones · 2d ago
HLS Therapeutics CEO to Present at Planet MicroCap Toronto Conference
TipRanks · 10/27 21:12
HLS Therapeutics Revamps Board to Support Next Phase of Growth
TipRanks · 10/01 11:39
HLS Therapeutics Earnings Call Highlights CV Growth
TipRanks · 08/21 00:26
HLS Therapeutics upgraded to Buy from Hold at Canaccord
TipRanks · 08/17 08:06
Stifel Nicolaus Reaffirms Their Hold Rating on HLS Therapeutics Inc (HLS)
TipRanks · 08/14 16:36
HLS Therapeutics Earns Reiterated Buy Rating from David Martin on Strong 2Q Results and Clozaril Recovery; C$12 Price Target Maintained
TipRanks · 08/13 13:55
Stocks in play: HLS Therapeutics Inc.
Barchart · 08/12 08:47
Stocks in play: HLS Therapeutics Inc.
Barchart · 07/29 08:57
Stocks in play: HLS Therapeutics Inc.
Barchart · 06/23 09:58
HLS Therapeutics resumed with a Hold at Canaccord
TipRanks · 05/19 17:25
HLS Therapeutics: Buy Rating Reiterated as Analyst Sees Nilemdo Upside with Unchanged $12 Price Target
TipRanks · 05/19 13:45
HLS Therapeutics Q1 Earnings Call Highlights
Barchart · 05/16 07:06
HLS Therapeutics reports Q1 results
Seeking Alpha · 05/15 15:59
Stocks in play: HLS Therapeutics Inc.
Barchart · 05/15 09:17
HLS Therapeutics to Highlight CNS and Cardiovascular Portfolio at Bloom Burton Investor Conference
TipRanks · 04/14 11:44
More
Webull provides a variety of real-time HLTRF stock news. You can receive the latest news about Hls Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About HLTRF
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.